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Splenic uptake on FDG PET/CT 
correlates with Kikuchi‑Fujimoto 
disease severity
Hye Seong1,3,4, Yong Hyu Jeong2,4, Woon Ji Lee1, Jun Hyoung Kim1, Jung Ho Kim1, 
Jin Young Ahn1, Su Jin Jeong1, Jun Yong Choi1, Yoon Soo Park1, Joon Sup Yeom1, 
Young Goo Song1, Arthur Cho2* & Nam Su Ku1*
Kikuchi‑Fujimoto disease (KFD) is usually self‑limiting, but prolonged systemic symptoms often result 
in frequent hospital visits, long admission durations, or missed workdays. We investigated the role of 
fluorine‑18 fluoro‑2‑deoxy‑D‑glucose (18F‑FDG) positron emission tomography/computed tomography 
(PET/CT) in assessing KFD severity. We reviewed the records of 31 adult patients with pathologically 
confirmed KFD who underwent 18F‑FDG PET/CT between November 2007 and April 2018 at a tertiary‑
care referral hospital. Disease severity was assessed using criteria based on clinical manifestations of 
advanced KFD. Systemic activated lymph nodes and severity of splenic activation were determined 
using semi‑quantitative and volumetric PET/CT parameters. The median of the mean splenic 
standardized uptake value  (SUVmean) was higher in patients with severe KFD than those with mild 
KFD (2.38 ± 1.18 vs. 1.79 ± 0.99, p = 0.058). Patients with severe KFD had more systemically activated 
volume and glycolytic activity than those with mild KFD (total lesion glycolysis: 473.5 ± 504.4 vs. 
201.6 ± 363.5, p = 0.024). Multivariate logistic regression showed that myalgia (odds ratio [OR] 0.035; 
95% confidence interval [CI] 0.001–0.792; p = 0.035), total lymph node  SUVmax (cutoff 9.27; OR 24.734; 
95% CI 1.323–462.407; p = 0.032), and spleen  SUVmean (cutoff 1.79; OR 37.770; 95% CI 1.769–806.583; 
p = 0.020) were significantly associated with severe KFD. 18F‑FDG PET/CT could be useful in assessing 
KFD severity.
Kikuchi-Fujimoto disease (KFD), also known as histiocytic necrotizing lymphadenitis, is a disease endemic to 
Asia and of unknown  etiology1–3. It usually develops in young adult women and is most commonly characterized 
by cervical lymphadenopathy and  fever4,5. KFD presents with various clinical features, ranging from absence of 
systemic symptoms to significant symptoms like night sweats, myalgia, weight loss, arthralgia, and hemophago-
cytic lymphohistiocytosis (HLH)6–9.
Although KFD is usually benign and self-limiting, patients with prolonged systemic symptoms are plagued 
with frequent hospital visits, long durations of admission, or missed  workdays10. Immunomodulating drugs, such 
as high-dose corticosteroids or intravenous immunoglobulins, which aid in shortening the clinical course of the 
disease, have been administered for treating patients with severe  KFD11,12. However, as there are no established 
markers for KFD severity, the determination of treatment options for KFD is dependent only on the clinician’s 
discretion, which may result in delayed treatment or a prolonged symptom duration.
Fluorine-18 fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomography/computed tomography 
(PET/CT) can be used to evaluate glucose utilization in multiple organs. Although 18F-FDG uptake has been 
predominately used to evaluate cancer metabolism, 18F-FDG PET/CT is used in clinical settings to assess local-
ized inflammatory foci and infectious diseases, such as tuberculosis, Q fever, infective endocarditis, vascular graft 
infection, chronic active Epstein–Barr virus infection, invasive fungal infection, and surgical site  infection13–17. 
Another advantage of 18F-FDG PET/CT is that PET metrics, such as standardized uptake value (SUV), metabolic 
tumor volume (MTV), and total lesion glycolysis (TLG), allow for the evaluation of the severity and quantifica-
tion of glycolysis in multiple organs, which serve as prognostic prediction parameters for survival in patients 
with solid  tumors18.
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The spleen is an important immune organ in both innate and adaptive immune responses and in regulating 
immune  homeostasis19. Studies have reported diffuse increased splenic 18F-FDG uptake in patients with lym-
phoma, infections, tuberculosis, and autoimmune  diseases20–23. Moreover, recent findings suggest that a diffuse 
increased FDG uptake was observed not only in the lymph nodes but also in the spleen in patients with  KFD24,25. 
However, the relationship between abnormal 18F-FDG uptake in patients with KFD and disease severity has not 
been established to date.
We hypothesized that glucose metabolism in the spleen and pathologic lymph nodes varies according to KFD 
severity because of the presence of systemic inflammation. Hence, we aimed to investigate the 18F-FDG uptake in 
the spleen and lymph nodes in patients with KFD and evaluate its performance as a disease severity parameter.
Methods
Patient selection. Inclusion criteria. We retrospectively reviewed the electronic medical records between 
November 2007 and April 2018 at a tertiary-care referral hospital located in Seoul, Korea. We enrolled patients 
who had pathologically confirmed KFD and underwent 18F-FDG PET/CT in the same admission period.
Exclusion criteria. We excluded patients who did not meet the criteria to assess KFD severity.
Data collections. Data collected included age, sex, clinical manifestations, laboratory test values, histologic 
findings, treatment methods and durations, fever duration, and outcomes such as relapse. All procedures per-
formed in human studies were in accordance with the ethical standards of the institutional and/or national 
research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical 
standards. This study was approved by the Institutional Review Board of Yonsei University Health System Clini-
cal Trial Center (4-2019-0977). Since the study was retrospective and the study subjects were anonymized, the 
Institutional Review Board Review Board of Yonsei University Health System Clinical Trial Center waived the 
requirement for written consent from the patients.
Definition of severe KFD. For assessment of disease severity, we established the presence of severe KFD 
based on the clinical manifestations of advanced KFD  disease10,26–28. Severe KFD was defined as KFD with at least 
one of the following manifestations: encephalitis, peripheral neuropathy, HLH, long fever duration (> 7 days), 
or leukopenia (< 4000/μL).
Imaging technique. All patients fasted for at least 6 h before the PET/CT scans were taken. Serum glucose 
levels (preferably < 150 mg/dL) were measured followed by intravenous administration of 5.5 MBq/kg 18F-FDG 
(with a maximum of 400 MBq). PET and combined low-dose CT scans were performed with commercial PET/
CT scanners (Discovery STE, Discovery D600, Discovery D710 [GE Healthcare, Chicago, IL, USA], or Biograph 
TruePoint40 [Siemens Healthineers, Erlangen, Germany]) after 1 h. The PET scan was performed with an acqui-
sition time of 2 min per bed position in the 3-dimensional mode. PET data were reconstructed iteratively using 
an ordered subset expectation maximization algorithm with the low-dose CT datasets for attenuation correction.
Imaging analysis. For semi-quantitative and volumetric analysis, various metabolic PET parameters were 
measured including the maximum SUV  (SUVmax), MTV, and TLG in the lymph nodes as well as the mean SUV 
 (SUVmean) and TLG in the spleen using commercially available imaging software (MIM Software, Cleveland, 
OH, USA). All PET/CT images were read by two experienced nuclear medicine physicians. For background 
activity, a spherical volume of interest (VOI) with a diameter of 30 mm was drawn at the inferior right lobe of the 
liver, excluding the main ducts and vessels. The  SUVmean of that VOI was adopted as a threshold value to deter-
mine the boundaries of the pathologic lymph nodes in each PET/CT study. After SUV thresholding, FDG-avid 
regions were automatically segmented using the isocontour threshold method. The  SUVmax of the total lymph 
nodes was defined as the highest metabolic foci  (SUVmax) in all the metabolically active lymph nodes in the body. 
The total MTV of lymph nodes was defined as the sum of the MTVs of all individual focal lesions identified in 
the analysis. The TLG of each focal lesion was calculated by multiplying the  SUVmean and voxel number of that 
lesion. The total lymph node TLG of each patient was defined as the sum of the TLGs for all focal lesions in the 
analysis. The  SUVmean and TLG of the spleen were identified by manually drawing regions of interest on each 
slice of the attenuation-corrected axial PET images (Fig. 1).
Statistical analysis. All our statistical analysis were only two variables (mild, severe). Descriptive statis-
tics for continuous variables are presented as medians ± interquartile range (IQR), and categorical variables are 
shown as numbers (percentage). The Mann–Whitney U test was performed to analyze differences between the 
mild and severe groups, while the χ2 test or Fisher’s exact test was performed on categorical data using SPSS 25.0 
(IBM, Armonk, NY, USA). To determine independent predictors of severity in the KFD group, we performed 
a multivariable analysis with a logistic regression model including risk factors associated with a p value of less 
than 0.05 in the univariate analysis. Differences were considered to be statistically significant at a 2-sided p value 
of less than 0.05.
Receiver operating characteristic (ROC) analysis was used to describe the relationship between FDG uptake 
and disease severity. MedCalc software (version 19.1, Ostend, Belgium) was used to analyze the data. Results 
of 18F-FDG PET/CT in the severe group were compared with those in the mild group to assess the diagnostic 
performance of 18F-FDG PET/CT in evaluating the degree of severity of KFD. The diagnostic performance was 
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expressed in terms of sensitivity, specificity, Youden index, positive predictive value (PPV), and negative predic-
tive value (NPV).
Results
Patient characteristics. The baseline characteristics of the 31 patients with KFD who underwent 18F-FDG 
PET/CT are divided into two groups—mild and severe KFD—and summarized in Table 1. The p values shown 
are the result from just two variables (mild, severe). All patients had been confirmed with KFD based on the 
pathological findings of a biopsy. The median age was 27.5 years (IQR, 28 years), and 13 patients were male 
(41.9%). The most commonly affected site of lymphadenopathy was the neck (n = 18; 58.1%), followed by the 
axilla (n = 7; 22.6%). In terms of systemic symptoms, almost every patient in our study presented with a fever 
(n = 30; 96.8%). Among the study patients, 8 (25.8%) patients were categorized into the mild and 23 (74.2%) 
into the severe KFD group. There were significant differences in age (38.0 ± 29 vs. 26.0 ± 18 years, p = 0.038) and 
lactate dehydrogenase (LDH) levels (310.5 ± 298 vs. 612.5 ± 672, p = 0.033). However, there were no significant 
differences in sex (57.1% vs. 37.5%, p = 0.354), sites of lymphadenopathy, or systemic symptoms between the 
mild and severe groups.
Comparison of PET/CT parameters according to the severity of KFD. We investigated the loca-
tions, metabolic activity, and size of hypermetabolic lymph nodes on 18F-FDG PET/CT images. The findings 
from the 18F-FDG PET/CT examinations are presented in Table 1. We identified hypermetabolic lymph nodes in 
31 patients with  SUVmax values from the neck, axilla, mediastinum, and the abdominopelvic area. Hypermeta-
bolic lymph nodes were observed in the necks of 18 patients, axillae of 7, mediastina of 4, and abdomens and 
pelvis of two patients. The median values of  SUVmax, MTV, and TLG of 18F-FDG uptake in affected lymph nodes 
were 10.65 ± 7.64, 97.95 ± 112.29, and 398.73 ± 464.08, respectively. The 18F-FDG uptake in the spleen  (SUVmean, 
2.19 ± 1.14; TLG, 539.36 ± 395.69) was calculated for all patients.
The median 18F-FDG PET/CT parameters involving the lymph nodes, liver, and spleen were identified in the 
mild and severe groups. The spleen  SUVmean was higher in patients with severe KFD (1.79 ± 0.99 vs. 2.38 ± 1.18, 
p = 0.058). The median values of total lymph node  SUVmax (8.19 ± 7.10 vs. 11.68 ± 7.33, p = 0.214), MTV 
(61.85 ± 118.32 vs. 99.36 ± 120.21, p = 0.104), and total lymph node TLG (201.57 ± 363.45 vs. 473.52 ± 504.44, 
p = 0.024) were higher in the severe group than in the mild group, indicating a higher 18F-FDG uptake in the 
severe group.
Figure 1.  Maximum intensity projection images of representative mild and severe Kikuchi-Fujimoto disease 
patients with lesion segmentation. (a) A patient with severe Kikuchi-Fujimoto disease. Systemic increase in 18F-
FDG uptake in the spleen and lymph nodes is seen. (b) A patient with mild Kikuchi-Fujimoto disease. Lesser 
FDG-avid lymph nodes are seen.
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Diagnostic performance of 18F‑FDG PET/CT in the prediction of KFD severity. Severity predic-
tions were made by analyzing the area under the curve (AUC) of the ROC (Fig. 2), and the corresponding sta-
tistics are shown in Table 2. Using the definition of severe KFD as a diagnostic criterion to separate the severe 
group from the mild group, ROC curve analysis determined the most sensitive and specific cutoff values for total 
lymph node TLG, spleen  SUVmean, total lymph node MTV, spleen TLG, and total lymph node  SUVmax as 429.99, 
1.79, 34.72, 296.06, and 9.27, respectively. With these cutoff values, total lymph node TLG (77.2%) and spleen 
 SUVmean (72.8%) were found to be more accurate than the other parameters.
Predictive factors for KFD severity. We evaluated the predictive factors for severe KFD. A univariate 
and multivariable analysis of severity in KFD was performed and is presented in Table 3 and Table S1. In the uni-
variate logistic regression, myalgia (odds ratio [OR] 0.150; 95% confidence interval [CI] 0.024–0.946; p = 0.044), 
total lymph node  SUVmax (cutoff 9.27) (OR 8.500; 95% CI 1.335–54.127; p = 0.023), total lymph node MTV (cut-
off 34.72) (OR 6.667; 95% CI 1.057–42.065; p = 0.044), total lymph node TLG (cutoff 429.99) (OR 10.889; 95% CI 
1.140–103.977; p = 0.038), spleen  SUVmean (cutoff 1.79) (OR 11.111; 95% CI 1.701–72.564; p = 0.012), and spleen 
TLG (cutoff 296.06) (OR 10.500; 95% CI 1.412–78.059; p = 0.022) were statistically significant. The multivari-
ate logistic regression model showed that myalgia (OR 0.035; 95% CI 0.001–0.792; p = 0.035), total lymph node 
 SUVmax (cutoff 9.27) (OR 24.734; 95% CI 1.323–462.407; p = 0.032), and spleen  SUVmean (cutoff 1.79) (OR 37.770; 
95% CI 1.769–806.583; p = 0.020) were significantly associated with severe KFD.
Discussion
18F-FDG PET/CT can be used to investigate various inflammatory and infectious diseases and benign  disorders29. 
Due to the advantages of 18F-FDG PET/CT in the systematic evaluation of fever of unknown  origin30, 18F-FDG 
uptake has often been assessed in the diagnostic workup of KFD. Alshammari et al. reported that 18F-FDG uptake 
Table 1.  Patient characteristics and results of univariate analysis for predicting the severity of Kikuchi-
Fujimoto disease. WBC, white blood cell count; CRP, C-reactive protein; ESR, erythrocyte sedimentation 
rate; LDH, lactate dehydrogenase; PET/CT, positron emission tomography/computed tomography;  SUVmax, 
maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis;  SUVmean, 
mean standardized uptake value Continuous variables are presented as means ± standard deviation and 
medians ± interquartile range (3rd interquartile range-1st interquartile range), and categorical variables are 
presented as numbers (percentage) *Statistical analysis performed mild and severe KFD.
Characteristics Total (n = 31) Mild (n = 8)* Severe (n = 23)* p value*
Age (years) 27.5 ± 28 38.0 ± 29 26.0 ± 18 0.038
Sex (male, %) 13 (41.9) 3 (37.5) 10 (43.5) > 0.999
Lymphadenopathy, yes (%)
 Cervical 18 (58.1) 5 (62.5) 13 (56.5) > 0.999
 Axillary 7 (22.6) 2 (25.0) 5 (21.7) > 0.999
 Mediastinal 2 (6.5) 1 (12.5) 1 (4.3) 0.456
 Abdominopelvic 4 (12.9) 0 (0.0) 4 (17.4) 0.550
Systemic symptoms
 Fever 30 (96.8) 8 (100.0) 22 (95.7) > 0.999
 Night sweat 7 (22.6) 2 (25.0) 5 (21.7) > 0.999
 Sore throat 4 (12.9) 2 (25.0) 2 (8.7) 0.268
 Weight loss 5 (16.1) 2 (25.0) 3 (13.0) 0.583
 Rash 8 (25.8) 3 (37.5) 5 (21.7) 0.393
 Myalgia 7 (22.6) 4 (57.1) 3 (42.9) 0.053
 Arthralgia 5 (16.1) 3 (37.5) 2 (8.7) 0.093
 Nausea 4 (12.9) 1 (12.5) 3 (13.0) > 0.999
 Headache 2 (6.5) 1 (12.5) 1 (4.3) 0.456
Laboratory findings
 WBC  (103/ul) 3.720 ± 4.52 6.645 ± 3.64 2.595 ± 1.97 0.002
 CRP (mg/L) 22.75 ± 73.35 71.93 ± 107.50 15.9 ± 51.71 0.091
 ESR (mm/h) 48.0 ± 39.75 67.0 ± 40.5 47.5 ± 43.5 0.348
 LDH (IU/L) 505.5 ± 604 310.5 ± 298 612.5 ± 672 0.033
PET/CT parameters
 Total lymph nodes  SUVmax 10.65 ± 7.64 8.19 ± 7.10 11.68 ± 7.33 0.214
 Total lymph nodes MTV 97.95 ± 112.29 61.85 ± 118.32 99.36 ± 120.21 0.104
 Total lymph nodes TLG 398.73 ± 464.08 201.57 ± 363.45 473.52 ± 504.44 0.024
 Spleen  SUVmean 2.19 ± 1.14 1.79 ± 0.99 2.38 ± 1.18 0.058
 Spleen TLG 539.24 ± 395.69 391.78 ± 528.87 548.73 ± 380.91 0.162
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can be detected not only in the generalized lymph nodes but also in the spleen in patients with  KFD24. Another 
study reported that the spleen showed increased 18F-FDG uptake in patients with febrile autoimmune disease 
and is associated with an increased risk of all-cause in-hospital  mortality22.
In this study, myalgia was found to be correlated with mild KFD. This may be because patients with mild 
KFD often present with myalgia at the time of diagnosis. Furthermore, patients presenting with myalgia as a 
systemic symptom are usually evaluated for the disease earlier than those who do not present with myalgia. We 
investigated the values of 18F-FDG PET/CT in patients with severe KFD to determine whether they can be used 
as predictive factors for disease severity. Among the various 18F-FDG PET/CT parameters, total lymph node 
 SUVmax and spleen  SUVmean were significantly associated with severe KFD. 18F-FDG uptake was significantly 
higher not only in the affected lymph nodes but also in the spleen in severe KFD. In multivariate logistic regres-
sion analysis, total lymph node  SUVmax with a cutoff value higher than 9.27 and spleen  SUVmean with a cutoff 
value higher than 1.79 were independent predictors of KFD severity. Increased total lymph node  SUVmax and 
spleen  SUVmean might be useful for predicting the disease course when clinical or laboratory data are not avail-
able or are not confirmed. We have shown, using multiple multivariable models, that not only the intensity of 
inflammatory response in lymph nodes  (SUVmax), but also the amount of activated lymph nodes (MTV, TLG) is 
correlated with KFD severity. Similarly, we have shown that spleen intensity  (SUVmax) as well as splenic metabolic 
size (MTV) is also correlated with KFD severity.
The spleen is the largest lymphoid organ in the human body that regulates blood flow and filters 
 microorganisms19. As a specialized immune organ, the spleen has various functions, such as clearance of micro-
organisms, the site of development for lymphocytes (both T and B), release of immunoglobulins, and production 
of immune  mediators31. Generally, 18F-FDG uptake is related to tissue metabolism, which may explain why an 
increased 18F-FDG uptake in the spleen may reflect increased glucose consumption in the spleen in the event of 
an  infection21. A recent study demonstrated that current inflammation could result in diffuse splenic 18F-FDG 
 uptake32. Therefore, we presume that increased diffuse 18F-FDG uptake in the spleen can be noted in many 
Figure 2.  Receiver operating characteristic curve of metabolic parameters in Kikuchi-Fujimoto disease. The 
areas under the curve (AUC) for total lymph nodes, TLG, and spleen  SUVmean are higher than that of total 
lymph nodes MTV.  SUVmean, mean standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion 
glycolysis.
Table 2.  Diagnostic performance of positron emission tomography/computed tomography for the severity of 
Kikuchi-Fujimoto disease. PPV, positive predictive value; NPV, negative predictive value;  SUVmax, maximum 
standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis;  SUVmean, mean 
standardized uptake value
Parameters Cutoff Sensitivity (%) Specificity (%) Accuracy (%) Youden index PPV (%) NPV (%)
Total lymph nodes  SUVmax 9.27 73.9 75.0 64.9 0.4891 89.5 50.0
Total lymph nodes MTV 34.72 87.0 50.0 69.6 0.3696 83.3 57.1
Total lymph nodes TLG 429.99 60.9 87.5 77.2 0.4837 93.3 43.7
Spleen  SUVmean 1.79 87.0 62.5 72.8 0.4946 87.0 62.5
Spleen TLG 296.06 91.3 50.0 66.8 0.4130 84.0 66.7
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inflammatory diseases reflecting the activation of the immune system in the spleen. This relationship between 
splenic glucose metabolism and inflammation may help explain our results.
There are several limitations of this study. First, this was a retrospective study. Second, our study population 
was small due to the low prevalence of KFD and the high cost of 18F-FDG PET/CT. Finally, we defined severe KFD 
arbitrarily. Since the severity criteria of KFD have not been previously defined, we defined severe KFD based on 
previous reports assessed factors associated with a severe clinical course and fetal complications of  KFD3,10,26–28,33 
and our clinical experience. Despite these limitations, our study is the first, to the best of our knowledge, to 
evaluate the potential association between 18F-FDG PET/CT parameters and KFD severity.
Our study suggests that 18F-FDG PET/CT can be a useful tool to assess disease severity in patients with KFD 
as a complement to laboratory and clinical findings. Further studies with larger populations are warranted to 
validate our results regarding the role of 18F-FDG PET/CT in determining KFD severity.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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